AC Immune Regains Global Rights to Crenezumab and Semorinemab Following Termination of Roche Collaboration

Jan 22, 2024 22:45 CST Updated 22:45

AC Immune

Biopharmaceutical Manufacturer

Roche

Oncology Drug Research, Development, and Manufacturing

Today, AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that it will regain the rights to the anti-Aβ antibody crenezumab and the anti-Tau antibody semorinemab following the termination of its collaboration agreement with Genentech and Roche, members of the Roche Group.GlobalAll rights. Both antibodies have been evaluated in clinical studies for Alzheimer's disease (AD). AC Immune will also regain the rights to clinically test existing GMP drugs and related data generated under each agreement. Before deciding on potential further development and other opportunities, AC Immune will carefully review and evaluate the available datasets, including the final open-label extension results of the Lauriet trial.

AC Immune and Genentech Reach AgreementApproximately USD 770 millionCooperation,Genentech Acquires Two Alzheimer's Antibody PipelinesClinical development and commercialization rights.

Dr. Andrea Pfeifer, CEO of AC Immune SA, said:"AC Immune is highly focused on advancing its three active immunotherapies through its precision medicine platform. These candidates are under development in potentially registrational Phase 2 clinical trials, including the recently initiated first pre-symptomatic Alzheimer’s prevention study. This approach leverages the patient's own immune system to slow disease onset and ultimately prevent neurodegenerative conditions, with the potential to revolutionize the treatment of these diseases. With our partner’s recent milestone payment in the Tau active immunotherapy program, combined with the $50 million financing secured in December, we are well-funded through 2026 to advance multiple high-value development programs."

Follow the official account below to see the world!